

October 5, 2016

MilliporeSigma's Udit Batra Receives CPhI's 'CEO of the Year' Award

- **Company also wins two awards for excellence in innovation for Parateck® SRP 80 and Emprove® program**

Billerica, Massachusetts, October 5, —[MilliporeSigma](#) today announced that CEO Udit Batra was named "CEO of the Year" for 2016 by CPhI Pharma for his commitment to furthering life science innovation globally.

The company also won two CPhI Pharma Awards—one for excellence in excipients and formulation development and another for regulatory procedures and compliance. CPhI announced the awards at the organization's annual awards gala on Oct. 4 in Barcelona, Spain.

"As advances in drug discovery yield more complex therapies, drug development and manufacturing must innovate at even a faster pace," said Udit Batra, CEO of MilliporeSigma. "At MilliporeSigma, we will continue to empower researchers and scientists with solutions that improve drug development quality and efficiency, helping them solve their toughest problems. On behalf of the company, I am honored to receive this award."

Recognition from this prestigious organization showcases some of the company's world-class technologies and solutions for researchers, drug developers and clinical lab customers working to treat disease.



News Release

The CPhI Pharma Awards acknowledged MilliporeSigma's groundbreaking innovations in technology, formulation, regulatory procedures and product development. The company received the following technology awards:

- [Parteck® SRP 80](#) won for "Excipients and Formulation Development." Parteck® SRP 80 is a functional direct compressible excipient designed for oral sustained-release formulations. It is fully synthetic for batch-to-batch and performance consistency and enhances the bioavailability of actives.
- [The Improve® program](#) won for "Regulatory Procedures and Compliance." The program provides documentation and regulatory information on materials used in the manufacture of drug products. This information enhances transparency, facilitates manufacturers' risk assessment workflows and supplier qualification.

CPhI is a global organization that connects people within the pharmaceutical sector and creates opportunities for pharma companies to develop new business, meet customers, launch new products, promote brands and expand into new markets. The CPhI Pharma Awards recognize life science firms that turn inspiration into innovation and celebrate thinkers and creators that are breaking new ground in formulation, process development, packaging and technology.

All Merck KGaA, Darmstadt, Germany news releases are distributed by email at the same time they become available on the EMD Group website. In case you are a resident of the U.S. or Canada please go to www.emdgroup.com/subscribe to register again for your online subscription of this service as our newly introduced geo-targeting requires new links in the email. You may later change your selection or discontinue this service.

About the Life Science Business of Merck KGaA, Darmstadt, Germany

The life science business of Merck KGaA, Darmstadt, Germany, which operates as MilliporeSigma in the U.S. and Canada, has 19,000 employees and 65 manufacturing sites worldwide, with a portfolio of more than 300,000 products enabling scientific discovery. Udit Batra is the global chief executive officer of MilliporeSigma.

Merck KGaA, Darmstadt, Germany completed its \$17 billion acquisition of Sigma-Aldrich in November 2015, creating a leader in the \$125 billion global life science industry.

Merck KGaA of Darmstadt, Germany is a leading company for innovative and top-quality high-tech products in healthcare, life science and performance materials. The company has six businesses – Biopharmaceuticals, Consumer Health, Allergopharma, Biosimilars, Life Science and Performance



News Release

Materials – and generated sales of €12.85 billion in 2015. Around 50,000 employees work in 66 countries to improve the quality of life for patients, to foster the success of customers and to help meet global challenges.

Merck KGaA, Darmstadt, Germany is the world's oldest pharmaceutical and chemical company – since 1668, the company has stood for innovation, business success and responsible entrepreneurship. Holding an approximately 70 percent interest, the founding family remains the majority owner of the company to this day. Merck KGaA, Darmstadt, Germany holds the global rights to the name and the trademark "Merck" internationally except for the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.